BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

They're off to a fast start, but the companies still have a long ways to go.

Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial

MAINZ, Germany and NEW YORK, April  29, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.

Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany

Pfizer's European biotech partner will soon begin early-stage testing of four experimental SARS-CoV-2 vaccines.

BioNTech Gets Green Light to Start Coronavirus Vaccine Trials in Germany

The biotech and its partner, Pfizer, will soon begin the first clinical trials of a coronavirus vaccine in Germany.

Shares of BioNTech Soar on a Coronavirus Vaccine Announcement

MAINZ, Germany and NEW YORK, April  22, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection. BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program. Pfizer and BioNTech will also conduct trials for BNT162 in the United States upon regulatory approval, which is expected shortly. 

BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BioNTech (BNTX) Soars: Stock Adds 5.2% in Session

Drugmaker Pfizer said Thursday that it is working on a promising treatment for coronavirus, as well as vaccine. The drugmaker said preclinical studies showed that an unspecified compound that was originally used to treat SARS — a different coronavirus — has shown potential in battling the dangerous illness.

Pfizer working on promising coronavirus treatment, vaccine

The enormity of the coronavirus pandemic has forced biopharma companies to step up efforts to expeditiously develop vaccines and treatments for COVID-19.

Pfizer, BioNTech, Arcturus Share Timelines For Human Testing As COVID-19 Vaccine Development Intensifies

Gilead Sciences

Pfizer stock jumped Thursday after the pharma giant identified a potential coronavirus treatment and inked a deal with BioNTech for a vaccine. Gilead updated its remdesivir studies.

Covid Report: Pfizer Selects Lead Coronavirus Drug; Gilead Updates Tests

The two drugmakers also revealed financial details of their SARS-CoV-2 vaccine collaboration.

Pfizer and BioNTech Aim to Start Testing Coronavirus Vaccines in Humans by Late April

Pfizer Inc. (NYSE: PFE) and BioNTech S.E.

Will the Pfizer-BioNTech Collaboration Be a Winner in the Fight Against COVID-19?

Shares of Pfizer Inc. PFE, +2.94% were up 0.6% in premarket trading on Thursday after the drugmaker disclosed it is paying BioNTech BNTX, -1.42% $185 million for their COVID-19 vaccine development collaboration, with additional possible future milestone payments up to $563 million.

Pfizer discloses $185 million upfront payment to BioNTech for COVID-19 vaccine program

MAINZ, Germany, and NEW YORK, April  09, 2020  (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

AstraZeneca

GlaxoSmithKline

Moderna

Sanofi

Telesis Bio Inc

Biotech and big pharma are putting vaccines using messenger RNA to the coronavirus test.

Is mRNA the Key to a Coronavirus Vaccine?

The coronavirus vaccine developer's stock is up a whopping 252% since its IPO in October.

Why BioNTech Stock Soared 66% in March While the Market Plunged

BioNTech SE's (BNTX) CEO Ugur Sahin on Q4 2019 - Earnings Call Transcript

Amazon

Chewy

Clorox

Citrix Systems

Hormel Foods

Kroger

Netflix

Okta

RingCentral

J. M. Smucker

Teladoc

Zoom Video

It goes without saying that 2020 has been a very challenging year. The 11-year old stock raging bull stock market over the course of a month has died and turned into a roaring bear market with the major equity indexes down over 30% so far from the top.

15 Stocks Still Rising Against the Roaring Bear Market and the Coronavirus

Eli Lilly

Takeda Pharmaceutical

The battle to defeat the coronavirus will be won. But victory won't come as quickly as anyone would like.

Big Pharma's Fight Against the Coronavirus Pandemic: Good News and Bad News

Investors are still excited about the biotech's coronavirus vaccine collaboration with Pfizer.

Why BioNTech Stock Is Skyrocketing 46.4% Higher Today

BioNTech SE (NASDAQ: BNTX) stock jumped on Tuesday and went even higher early on Wednesday.

BioNTech’s Coronavirus Vaccine Just Got Strong Backing

The partnership announced today will see the two pharmaceutical companies join forces in coronavirus battle.

Pfizer Joins Forces With BioNTech For COVID-19 Vaccine Co-Development

Pharma giant Pfizer announced on Tuesday that it’s working with BioNTech, a German company working on new kinds of immunotherapy treatments, on a potential COVID-19 vaccine. The joint effort, confirmed Tuesday via a signed letter of intent, will see both partners work together on a a messenger RNA-based vaccine that will seek to prevent people […]

Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine

Pfizer Inc. PFE, -7.73% said Tuesday it will help develop and distribute BioNTech SE's COVID-19 vaccine candidate, though the deal excludes China.

BioNTech, Pfizer to develop COVID-19 vaccine candidate

NEW YORK and MAINZ, Germany, March  17, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.

News for BioNTech SE Stock (BNTX)